Newsfeeds Archive - Page 443 of 19074

8 minute read

How 3 Chilean Brothers Built A Global Cannabis Platform Embraced By Big Sponsors Like Adidas And Crocs

June 2, 2:26 PM

It was the year 2013 and Santiago, Chile’s capital, was unknowingly about to become the epicenter of a digital phenomenon that would redefine the perception of cannabis in the Spanish-speaking world.

ADDYY

1 minute read

Salesforce And Celsius Were Among The 10 Biggest Large Cap Losers Last Week: Are These In Your Portfolio?

By Lekha Gupta

June 2, 11:12 AM

10 large-cap stocks worst performers last week: MongoDB, Nutanix, DraftKings, Salesforce, Samsara, Celsius, Agilent, Snowflake, ServiceNow, Hormel. Are they in your portfolio?

1 minute read

Events
News

Genmab, BioNTech Announced Data At ASCO, Showing Investigational Acasunlimab In Combination With Pembrolizumab Resulted In 12-month Overall Survival Rate of 69% In Patients With Previously Treated Metastatic Non-small Cell Lung Cancer

By Charles Gross

June 2, 11:02 AM

Genmab A/S (NASDAQ:GMAB) and BioNTech SE (NASDAQ:BNTX) todayannounced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also

BNTX

1 minute read

NIO And Best Buy Were Among 10 Stocks That Shined The Brightest Last Week: Are They In Your Portfolio?

By Lekha Gupta

June 2, 10:57 AM

Top stocks last week: BIRK, BURL, DKS, BBY, CAVA, NIO, HPQ, MRO, RL, ONON. Strong earnings, raised guidance, and analysts' price target boosts.

BBY

1 minute read

News

Reported Saturday, Launch Of Boeing’s Starliner Spacecraft Was Delayed Saturday Minutes Before Takeoff, Due To An Issue Related To A Computer System

By Charles Gross

June 2, 10:51 AM

https://abcn

1 minute read

Events
News

Nanobiotix Announced New Data At ASCO 2924, Showing 48% ORR In Evaluable Anti-PD-1 Naïve Patients (n=25); 28% ORR In Evaluable Anti-PD-1 Resistant Patients (n=25) As Per RECIST 1.1

By Charles Gross

June 2, 10:42 AM

NANOBIOTIX (NASDAQ:NBTX) today announced new data from Study 1100, a US Phase 1 dose escalation and dose expansion study evaluating radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoint

NBTX

1 minute read

Events
News

Intellia Therapeutics Announced Single Dose Of Ntla-2002 Led To A 98% Mean Reduction In Monthly Hereditary Angioedema Attack Rate, With An Average Follow-up Of Over 20 Months Across All Patients

By Charles Gross

June 2, 10:38 AM

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced long-term data from the Phase 1 portion of the

NTLA

1 minute read

Events
News

Gilead And Arcus Announced Etrumadenant Plus Zimberelimab, FOLFOX, And Bevacizumab Reduce Death Risk By 63% And Disease Progression by 73% vs Regorafenib In Phase 1b/2 Trial For Third-Line Metastatic Colorectal Cancer

By Charles Gross

June 2, 10:36 AM

Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine

GILD

2 minute read

Cathie Wood’s Ark Investment Drops Plans For Spot-Ether ETF, Says It Will Focus On Spot Bitcoin ETF Instead

By Bibhu Pattnaik

June 2, 10:15 AM

Cathie Wood’s Ark Investment Management has withdrawn from the race to launch an ETF directly investing in Ether (CRYPTO: ETH).

BLK

1 minute read

ALX Oncology Reported Phase 1 ASPEN-07 Data In in Patients with Advanced Bladder Cancer AT ASCO 2024; Initial Activity Showed Tumor Reduction In The Majority Of Evaluable Patients

By Charles Gross

June 2, 10:13 AM

ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (NASDAQ: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented dataALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (NASDAQ:

ALXO